The demand for the anti-malaria drug hydroxychloroquine has been found to be effective in treating coronavirus infected patients. Many countries of the world including America are demanding hydroxychloroquine from India. India on Tuesday lifted its ban on exports. Meanwhile, the pharma sector has assured that there is sufficient stock of hydroxychloroquine in the country. Also, pharmaceutical companies are ready to increase production according to the demand of the country and the world.
India has Tuesday partially lifted the ban on the export of anti-malaria drug hydroxychloroquine, pledging to cooperate in combating the coronavirus. On March 25, the Indian government banned its exports after it came to know of its good effect on coronavirus patients.
In view of the humanitarian aspects of #COVID19 pandemic, it has been decided that India would licence paracetamol & Hydroxychloroquine in appropriate quantities to all our neighbouring countries who are dependent on our capabilities: Ministry of External Affairs (MEA) pic.twitter.com/W7Vox2sd2EAdvertisement
— ANI (@ANI) April 7, 2020
70 percent of production takes place in India
India is the largest exporter of this medicine. Sudarshan Jain, general secretary of the Indian Pharmaceutical Alliance (IPA) said, ‘India produces 70 percent of the total consumption of hydroxychloroquine in the world. Companies like Zydus, Cadila, and IPCA are major producers in the country.
‘Ready to increase production’
He further stated that the production capacity is sufficient to meet the current demand. Companies are willing to increase production if the need increases. Jain said, “The government has lifted the ban on 12 products and their mix. All aspects are being reviewed. The domestic demand and the demand for paracetamol and hydroxychloroquine will be met for export. He also said that there is a need to ensure that unnecessary shopping and hoarding are prevented. Its proper distribution should be ensured in the needy patients.
’24 million tablet consumption, 20 million capacity’
Ashok Kumar Madan, executive director of the Indian Drug Manufacturers Association said, “India requires 24 million tablets of hydroxychloroquine in a year. India currently has the capacity to manufacture hydroxychloroquine from 40 metric tons of raw materials annually. With this, we can make 200 million tablets of 200mg. ‘
Madan said this shows that India has the capacity available. We have to see how much the country needs for treatment and prevention. Companies have started increasing capacity. Hydroxychloroquine is suddenly in the limelight for the treatment and prevention of COVID-19.
Mustakim is our resident guy with a degree in English Literature, he LOVES to write about Entertainment and loves to explore the latest world Technology News around the Globe. It’s always interesting to read what he posts. Mustakim keeps things very, very interesting indeed. He also writes for another Entertainment website on the Internet.